Editorial
Copyright ©2012 Baishideng. All rights reserved.
World J Hypertens. Oct 23, 2012; 2(5): 45-49
Published online Oct 23, 2012. doi: 10.5494/wjh.v2.i5.45
Nice new hypertension guidelines
Bernard Man Yung Cheung, Tommy Tsang Cheung
Bernard Man Yung Cheung, Tommy Tsang Cheung, Division of Clinical Pharmacology and Therapeutics, Department of Medicine, University of Hong Kong, Hong Kong, China
Author contributions: Both authors contributed equally to this article.
Correspondence to: Bernard Man Yung Cheung, PhD, FRCP, Professor, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China. mycheung@hku.hk
Telephone: +852-2-2554347 Fax: +852-2-8186474
Received: December 26, 2011
Revised: July 12, 2012
Accepted: July 23, 2012
Published online: October 23, 2012
Abstract

The National Institute for Clinical Excellence in the United Kingdom published a new set of guidelines on the management of primary hypertension in August 2011, reflecting some important changes in the diagnosis and treatment of hypertension. Ambulatory blood pressure measurement is now the new gold standard for diagnosis. Home blood pressure monitoring is a useful alternative for the diagnosis and monitoring of hypertension. Calcium channel blockers (CCB) and blockers of the renin-angiotensin system have surpassed diuretics and β-blockers as first line options. Patients younger than 55 should receive an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker if the former is not tolerated. Older patients should be started on a CCB. A thiazide diuretic can be added to these two groups for better blood pressure control, but. chorthalidone and indapamide are the preferred diuretics as they showed favorable outcomes in large clinical trials. Treatment with these three drug classes should be sufficient in the majority of patients, but if triple therapy is still insufficient, referral to a hypertension specialist is recommended. Additional diuretic therapy, spironolactone, or an α or β blocker can be used as the fourth line treatment.

Keywords: Hypertension, Guidelines, Angiotensin-converting enzyme inhibitor, The National Institute for Clinical Excellence